Skip to main content Skip to footer
HomeHome
 
  • Homepage
  • Searching for patents

    Patent knowledge

    Access our patent databases and search tools.

    Go to overview 

    • Overview
    • Technical information
      • Overview
      • Espacenet - patent search
      • European Publication Server
      • EP full-text search
    • Legal information
      • Overview
      • European Patent Register
      • European Patent Bulletin
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Overview
      • PATSTAT
      • IPscore
      • Technology insight reports
    • Data
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
      • Web services
      • Coverage, codes and statistics
    • Technology platforms
      • Overview
      • Plastics in transition
      • Water innovation
      • Space innovation
      • Technologies combatting cancer
      • Firefighting technologies
      • Clean energy technologies
      • Fighting coronavirus
    • Helpful resources
      • Overview
      • First time here?
      • Asian patent information
      • Patent information centres
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
    Image
    Plastics in Transition

    Technology insight report on plastic waste management

  • Applying for a patent

    Applying for a patent

    Practical information on filing and grant procedures.

    Go to overview 

    • Overview
    • European route
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
      • Appeals
      • Unitary Patent & Unified Patent Court
      • National validation
      • Request for extension/validation
    • International route (PCT)
      • Overview
      • Euro-PCT Guide – PCT procedure at the EPO
      • EPO decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
      • Training and events
    • National route
    • Find a professional representative
    • MyEPO services
      • Overview
      • Understand our services
      • Get access
      • File with us
      • Interact with us on your files
      • Online Filing & fee payment outages
    • Forms
      • Overview
      • Request for examination
    • Fees
      • Overview
      • European fees (EPC)
      • International fees (PCT)
      • Unitary Patent fees (UP)
      • Fee payment and refunds
      • Warning

    UP

    Find out how the Unitary Patent can enhance your IP strategy

  • Law & practice

    Law & practice

    European patent law, the Official Journal and other legal texts.

    Go to overview 

    • Overview
    • Legal texts
      • Overview
      • European Patent Convention
      • Official Journal
      • Guidelines
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
      • Unitary patent system
      • National measures relating to the Unitary Patent
    • Court practices
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
    Image
    Law and practice scales 720x237

    Keep up with key aspects of selected BoA decisions with our monthly "Abstracts of decisions”

  • News & events

    News & events

    Our latest news, podcasts and events, including the European Inventor Award.

    Go to overview 

     

    • Overview
    • News
    • Events
    • European Inventor Award
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the finalists
      • Nominations
      • European Inventor Network
      • The 2024 event
    • Young Inventor Prize
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
    • Press centre
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • Innovation and patenting in focus
      • Overview
      • Water-related technologies
      • CodeFest
      • Green tech in focus
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
      • The future of medicine
      • Materials science
      • Mobile communications
      • Biotechnology
      • Patent classification
      • Digital technologies
      • The future of manufacturing
      • Books by EPO experts
    • "Talk innovation" podcast

    Podcast

    From ideas to inventions: tune into our podcast for the latest in tech and IP

  • Learning

    Learning

    The European Patent Academy – the point of access to your learning

    Go to overview 

    • Overview
    • Learning activities and paths
      • Overview
      • Learning activities
      • Learning paths
    • EQE and EPAC
      • Overview
      • EQE - European qualifying examination
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Overview
      • Business and IP managers
      • EQE and EPAC Candidates
      • Judges, lawyers and prosecutors
      • National offices and IP authorities
      • Patent attorneys and paralegals
      • Universities, research centres and technology transfer centres (TTOs)
    Image
    Patent Academy catalogue

    Have a look at the extensive range of learning opportunities in the European Patent Academy training catalogue

  • About us

    About us

    Find out more about our work, values, history and vision

    Go to overview 

    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Overview
      • Official celebrations
      • Member states’ video statements
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Overview
      • Legal foundations
      • Member states of the European Patent Organisation
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Overview
      • Communiqués
      • Calendar
      • Documents and publications
      • Administrative Council
    • Principles & strategy
      • Overview
      • Our mission, vision, values and corporate policy
      • Strategic Plan 2028
      • Towards a New Normal
    • Leadership & management
      • Overview
      • President António Campinos
      • Management Advisory Committee
    • Sustainability at the EPO
      • Overview
      • Environmental
      • Social
      • Governance and Financial sustainability
    • Services & activities
      • Overview
      • Our services & structure
      • Quality
      • Consulting our users
      • European and international co-operation
      • European Patent Academy
      • Chief Economist
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Overview
      • Innovation actors
      • Policy and funding
      • Tools
      • About the Observatory
    • Procurement
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Sustainable Procurement Policy
      • About eTendering and electronic signatures
      • Procurement portal
      • Invoicing
      • General conditions
      • Archived tenders
    • Transparency portal
      • Overview
      • General
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
      • "Long Night"
    Image
    Patent Index 2024 keyvisual showing brightly lit up data chip, tinted in purple, bright blue

    Track the latest tech trends with our Patent Index

 
en de fr
  • Language selection
  • English
  • Deutsch
  • Français
Main navigation
  • Homepage
    • Go back
    • New to patents
  • New to patents
    • Go back
    • Your business and patents
    • Why do we have patents?
    • What's your big idea?
    • Are you ready?
    • What to expect
    • How to apply for a patent
    • Is it patentable?
    • Are you first?
    • Patent quiz
    • Unitary patent video
  • Searching for patents
    • Go back
    • Overview
    • Technical information
      • Go back
      • Overview
      • Espacenet - patent search
        • Go back
        • Overview
        • National patent office databases
        • Global Patent Index (GPI)
        • Release notes
      • European Publication Server
        • Go back
        • Overview
        • Release notes
        • Cross-reference index for Euro-PCT applications
        • EP authority file
        • Help
      • EP full-text search
    • Legal information
      • Go back
      • Overview
      • European Patent Register
        • Go back
        • Overview
        • Release notes archive
        • Register documentation
          • Go back
          • Overview
          • Deep link data coverage
          • Federated Register
          • Register events
      • European Patent Bulletin
        • Go back
        • Overview
        • Download Bulletin
        • EP Bulletin search
        • Help
      • European Case Law Identifier sitemap
      • Third-party observations
    • Business information
      • Go back
      • Overview
      • PATSTAT
      • IPscore
        • Go back
        • Release notes
      • Technology insight reports
    • Data
      • Go back
      • Overview
      • Technology Intelligence Platform
      • Linked open EP data
      • Bulk data sets
        • Go back
        • Overview
        • Manuals
        • Sequence listings
        • National full-text data
        • European Patent Register data
        • EPO worldwide bibliographic data (DOCDB)
        • EP full-text data
        • EPO worldwide legal event data (INPADOC)
        • EP bibliographic data (EBD)
        • Boards of Appeal decisions
      • Web services
        • Go back
        • Overview
        • Open Patent Services (OPS)
        • European Publication Server web service
      • Coverage, codes and statistics
        • Go back
        • Weekly updates
        • Updated regularly
    • Technology platforms
      • Go back
      • Overview
      • Plastics in transition
        • Go back
        • Overview
        • Plastics waste recovery
        • Plastics waste recycling
        • Alternative plastics
      • Innovation in water technologies
        • Go back
        • Overview
        • Clean water
        • Protection from water
      • Space innovation
        • Go back
        • Overview
        • Cosmonautics
        • Space observation
      • Technologies combatting cancer
        • Go back
        • Overview
        • Prevention and early detection
        • Diagnostics
        • Therapies
        • Wellbeing and aftercare
      • Firefighting technologies
        • Go back
        • Overview
        • Detection and prevention of fires
        • Fire extinguishing
        • Protective equipment
        • Post-fire restoration
      • Clean energy technologies
        • Go back
        • Overview
        • Renewable energy
        • Carbon-intensive industries
        • Energy storage and other enabling technologies
      • Fighting coronavirus
        • Go back
        • Overview
        • Vaccines and therapeutics
          • Go back
          • Overview
          • Vaccines
          • Overview of candidate therapies for COVID-19
          • Candidate antiviral and symptomatic therapeutics
          • Nucleic acids and antibodies to fight coronavirus
        • Diagnostics and analytics
          • Go back
          • Overview
          • Protein and nucleic acid assays
          • Analytical protocols
        • Informatics
          • Go back
          • Overview
          • Bioinformatics
          • Healthcare informatics
        • Technologies for the new normal
          • Go back
          • Overview
          • Devices, materials and equipment
          • Procedures, actions and activities
          • Digital technologies
        • Inventors against coronavirus
    • Helpful resources
      • Go back
      • Overview
      • First time here?
        • Go back
        • Overview
        • Basic definitions
        • Patent classification
          • Go back
          • Overview
          • Cooperative Patent Classification (CPC)
        • Patent families
          • Go back
          • Overview
          • DOCDB simple patent family
          • INPADOC extended patent family
        • Legal event data
          • Go back
          • Overview
          • INPADOC classification scheme
      • Asian patent information
        • Go back
        • Overview
        • China (CN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Chinese Taipei (TW)
          • Go back
          • Overview
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • India (IN)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
        • Japan (JP)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Korea (KR)
          • Go back
          • Overview
          • Facts and figures
          • Grant procedure
          • Numbering system
          • Useful terms
          • Searching in databases
        • Russian Federation (RU)
          • Go back
          • Overview
          • Facts and figures
          • Numbering system
          • Searching in databases
        • Useful links
      • Patent information centres (PATLIB)
      • Patent Translate
      • Patent Knowledge News
      • Business and statistics
      • Unitary Patent information in patent knowledge
  • Applying for a patent
    • Go back
    • Overview
    • European route
      • Go back
      • Overview
      • European Patent Guide
      • Oppositions
      • Oral proceedings
        • Go back
        • Oral proceedings calendar
          • Go back
          • Calendar
          • Public access to appeal proceedings
          • Public access to opposition proceedings
          • Technical guidelines
      • Appeals
      • Unitary Patent & Unified Patent Court
        • Go back
        • Overview
        • Unitary Patent
          • Go back
          • Overview
          • Legal framework
          • Main features
          • Applying for a Unitary Patent
          • Cost of a Unitary Patent
          • Translation and compensation
          • Start date
          • Introductory brochures
        • Unified Patent Court
      • National validation
      • Extension/validation request
    • International route
      • Go back
      • Overview
      • Euro-PCT Guide
      • Entry into the European phase
      • Decisions and notices
      • PCT provisions and resources
      • Extension/validation request
      • Reinforced partnership programme
      • Accelerating your PCT application
      • Patent Prosecution Highway (PPH)
        • Go back
        • Patent Prosecution Highway (PPH) programme outline
      • Training and events
    • National route
    • MyEPO services
      • Go back
      • Overview
      • Understand our services
        • Go back
        • Overview
        • Exchange data with us using an API
          • Go back
          • Release notes
      • Get access
        • Go back
        • Overview
        • Release notes
      • File with us
        • Go back
        • Overview
        • What if our online filing services are down?
        • Release notes
      • Interact with us on your files
        • Go back
        • Release notes
      • Online Filing & fee payment outages
    • Fees
      • Go back
      • Overview
      • European fees (EPC)
        • Go back
        • Overview
        • Decisions and notices
      • International fees (PCT)
        • Go back
        • Reduction in fees
        • Fees for international applications
        • Decisions and notices
        • Overview
      • Unitary Patent fees (UP)
        • Go back
        • Overview
        • Decisions and notices
      • Fee payment and refunds
        • Go back
        • Overview
        • Payment methods
        • Getting started
        • FAQs and other documentation
        • Technical information for batch payments
        • Decisions and notices
        • Release notes
      • Warning
    • Forms
      • Go back
      • Overview
      • Request for examination
    • Find a professional representative
  • Law & practice
    • Go back
    • Overview
    • Legal texts
      • Go back
      • Overview
      • European Patent Convention
        • Go back
        • Overview
        • Archive
          • Go back
          • Overview
          • Documentation on the EPC revision 2000
            • Go back
            • Overview
            • Diplomatic Conference for the revision of the EPC
            • Travaux préparatoires
            • New text
            • Transitional provisions
            • Implementing regulations to the EPC 2000
            • Rules relating to Fees
            • Ratifications and accessions
          • Travaux Préparatoires EPC 1973
      • Official Journal
      • Guidelines
        • Go back
        • Overview
        • EPC Guidelines
        • PCT-EPO Guidelines
        • Unitary Patent Guidelines
        • Guidelines revision cycle
        • Consultation results
        • Summary of user responses
        • Archive
      • Extension / validation system
      • London Agreement
      • National law relating to the EPC
        • Go back
        • Overview
        • Archive
      • Unitary Patent system
        • Go back
        • Travaux préparatoires to UP and UPC
      • National measures relating to the Unitary Patent 
    • Court practices
      • Go back
      • Overview
      • European Patent Judges' Symposium
    • User consultations
      • Go back
      • Overview
      • Ongoing consultations
      • Completed consultations
    • Substantive patent law harmonisation
      • Go back
      • Overview
      • The Tegernsee process
      • Group B+
    • Convergence of practice
    • Options for professional representatives
  • News & events
    • Go back
    • Overview
    • News
    • Events
    • European Inventor Award
      • Go back
      • Overview
      • The meaning of tomorrow
      • About the award
      • Categories and prizes
      • Meet the inventors
      • Nominations
      • European Inventor Network
        • Go back
        • 2024 activities
        • 2025 activities
        • Rules and criteria
        • FAQ
      • The 2024 event
    • Young Inventors Prize
      • Go back
      • Overview
      • About the prize
      • Nominations
      • The jury
      • The world, reimagined
      • The 2025 event
    • Press centre
      • Go back
      • Overview
      • Patent Index and statistics
      • Search in press centre
      • Background information
        • Go back
        • Overview
        • European Patent Office
        • Q&A on patents related to coronavirus
        • Q&A on plant patents
      • Copyright
      • Press contacts
      • Call back form
      • Email alert service
    • In focus
      • Go back
      • Overview
      • Water-related technologies
      • CodeFest
        • Go back
        • CodeFest Spring 2025 on classifying patent data for sustainable development
        • Overview
        • CodeFest 2024 on generative AI
        • CodeFest 2023 on Green Plastics
      • Green tech in focus
        • Go back
        • Overview
        • About green tech
        • Renewable energies
        • Energy transition technologies
        • Building a greener future
      • Research institutes
      • Women inventors
      • Lifestyle
      • Space and satellites
        • Go back
        • Overview
        • Patents and space technologies
      • Healthcare
        • Go back
        • Overview
        • Medical technologies and cancer
        • Personalised medicine
      • Materials science
        • Go back
        • Overview
        • Nanotechnology
      • Mobile communications
      • Biotechnology
        • Go back
        • Overview
        • Red, white or green
        • The role of the EPO
        • What is patentable?
        • Biotech inventors
      • Classification
        • Go back
        • Overview
        • Nanotechnology
        • Climate change mitigation technologies
          • Go back
          • Overview
          • External partners
          • Updates on Y02 and Y04S
      • Digital technologies
        • Go back
        • Overview
        • About ICT
        • Hardware and software
        • Artificial intelligence
        • Fourth Industrial Revolution
      • Additive manufacturing
        • Go back
        • Overview
        • About AM
        • AM innovation
      • Books by EPO experts
    • Podcast
  • Learning
    • Go back
    • Overview
    • Learning activities and paths
      • Go back
      • Overview
      • Learning activities: types and formats
      • Learning paths
    • EQE and EPAC
      • Go back
      • Overview
      • EQE - European Qualifying Examination
        • Go back
        • Overview
        • Compendium
          • Go back
          • Overview
          • Paper F
          • Paper A
          • Paper B
          • Paper C
          • Paper D
          • Pre-examination
        • Candidates successful in the European qualifying examination
        • Archive
      • EPAC - European patent administration certification
      • CSP – Candidate Support Programme
    • Learning resources by area of interest
      • Go back
      • Overview
      • Patent granting
      • Technology transfer and dissemination
      • Patent enforcement and litigation
    • Learning resources by profile
      • Go back
      • Overview
      • Business and IP managers
        • Go back
        • Overview
        • Innovation case studies
          • Go back
          • Overview
          • SME case studies
          • Technology transfer case studies
          • High-growth technology case studies
        • Inventor's handbook
          • Go back
          • Overview
          • Introduction
          • Disclosure and confidentiality
          • Novelty and prior art
          • Competition and market potential
          • Assessing the risk ahead
          • Proving the invention
          • Protecting your idea
          • Building a team and seeking funding
          • Business planning
          • Finding and approaching companies
          • Dealing with companies
        • Best of search matters
          • Go back
          • Overview
          • Tools and databases
          • EPO procedures and initiatives
          • Search strategies
          • Challenges and specific topics
        • Support for high-growth technology businesses
          • Go back
          • Overview
          • Business decision-makers
          • IP professionals
          • Stakeholders of the Innovation Ecosystem
      • EQE and EPAC Candidates
        • Go back
        • Overview
        • Paper F brain-teasers
        • Daily D questions
        • European qualifying examination - Guide for preparation
        • EPAC
      • Judges, lawyers and prosecutors
        • Go back
        • Overview
        • Compulsory licensing in Europe
        • The jurisdiction of European courts in patent disputes
      • National offices and IP authorities
        • Go back
        • Overview
        • Learning material for examiners of national officers
        • Learning material for formalities officers and paralegals
      • Patent attorneys and paralegals
      • Universities, research centres and TTOs
        • Go back
        • Overview
        • Modular IP Education Framework (MIPEF)
        • Pan-European Seal Young Professionals Programme
          • Go back
          • Overview
          • For students
          • For universities
            • Go back
            • Overview
            • IP education resources
            • University memberships
          • Our young professionals
          • Professional development plan
        • Academic Research Programme
          • Go back
          • Overview
          • Completed research projects
          • Current research projects
        • IP Teaching Kit
          • Go back
          • Overview
          • Download modules
        • Intellectual property course design manual
        • PATLIB Knowledge Transfer to Africa
          • Go back
          • The PATLIB Knowledge Transfer to Africa initiative (KT2A)
          • KT2A core activities
          • Success story: Malawi University of Science and Technology and PATLIB Birmingham
  • About us
    • Go back
    • Overview
    • The EPO at a glance
    • 50 years of the EPC
      • Go back
      • Official celebrations
      • Overview
      • Member states’ video statements
        • Go back
        • Albania
        • Austria
        • Belgium
        • Bulgaria
        • Croatia
        • Cyprus
        • Czech Republic
        • Denmark
        • Estonia
        • Finland
        • France
        • Germany
        • Greece
        • Hungary
        • Iceland
        • Ireland
        • Italy
        • Latvia
        • Liechtenstein
        • Lithuania
        • Luxembourg
        • Malta
        • Monaco
        • Montenegro
        • Netherlands
        • North Macedonia
        • Norway
        • Poland
        • Portugal
        • Romania
        • San Marino
        • Serbia
        • Slovakia
        • Slovenia
        • Spain
        • Sweden
        • Switzerland
        • Türkiye
        • United Kingdom
      • 50 Leading Tech Voices
      • Athens Marathon
      • Kids’ collaborative art competition
    • Legal foundations and member states
      • Go back
      • Overview
      • Legal foundations
      • Member states
        • Go back
        • Overview
        • Member states by date of accession
      • Extension states
      • Validation states
    • Administrative Council and subsidiary bodies
      • Go back
      • Overview
      • Communiqués
        • Go back
        • 2024
        • Overview
        • 2023
        • 2022
        • 2021
        • 2020
        • 2019
        • 2018
        • 2017
        • 2016
        • 2015
        • 2014
        • 2013
      • Calendar
      • Documents and publications
        • Go back
        • Overview
        • Select Committee documents
      • Administrative Council
        • Go back
        • Overview
        • Composition
        • Representatives
        • Rules of Procedure
        • Board of Auditors
        • Secretariat
        • Council bodies
    • Principles & strategy
      • Go back
      • Overview
      • Mission, vision, values & corporate policy
      • Strategic Plan 2028
        • Go back
        • Driver 1: People
        • Driver 2: Technologies
        • Driver 3: High-quality, timely products and services
        • Driver 4: Partnerships
        • Driver 5: Financial sustainability
      • Towards a New Normal
      • Data protection & privacy notice
    • Leadership & management
      • Go back
      • Overview
      • About the President
      • Management Advisory Committee
    • Sustainability at the EPO
      • Go back
      • Overview
      • Environmental
        • Go back
        • Overview
        • Inspiring environmental inventions
      • Social
        • Go back
        • Overview
        • Inspiring social inventions
      • Governance and Financial sustainability
    • Procurement
      • Go back
      • Overview
      • Procurement forecast
      • Doing business with the EPO
      • Procurement procedures
      • Dynamic Purchasing System (DPS) publications
      • Sustainable Procurement Policy
      • About eTendering
      • Invoicing
      • Procurement portal
        • Go back
        • Overview
        • e-Signing contracts
      • General conditions
      • Archived tenders
    • Services & activities
      • Go back
      • Overview
      • Our services & structure
      • Quality
        • Go back
        • Overview
        • Foundations
          • Go back
          • Overview
          • European Patent Convention
          • Guidelines for examination
          • Our staff
        • Enabling quality
          • Go back
          • Overview
          • Prior art
          • Classification
          • Tools
          • Processes
        • Products & services
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
          • Continuous improvement
        • Quality through networking
          • Go back
          • Overview
          • User engagement
          • Co-operation
          • User satisfaction survey
          • Stakeholder Quality Assurance Panels
        • Patent Quality Charter
        • Quality Action Plan
        • Quality dashboard
        • Statistics
          • Go back
          • Overview
          • Search
          • Examination
          • Opposition
        • Integrated management at the EPO
      • Consulting our users
        • Go back
        • Overview
        • Standing Advisory Committee before the EPO (SACEPO)
          • Go back
          • Overview
          • Objectives
          • SACEPO and its working parties
          • Meetings
          • Single Access Portal – SACEPO Area
        • Surveys
          • Go back
          • Overview
          • Detailed methodology
          • Search services
          • Examination services, final actions and publication
          • Opposition services
          • Formalities services
          • Customer services
          • Filing services
          • Key Account Management (KAM)
          • Website
          • Archive
      • Our user service charter
      • European and international co-operation
        • Go back
        • Overview
        • Co-operation with member states
          • Go back
          • Overview
        • Bilateral co-operation with non-member states
          • Go back
          • Overview
          • Validation system
          • Reinforced Partnership programme
        • Multilateral international co-operation with IP offices and organisations
        • Co-operation with international organisations outside the IP system
      • European Patent Academy
        • Go back
        • Overview
        • Partners
      • Chief Economist
        • Go back
        • Overview
        • Economic studies
      • Ombuds Office
      • Reporting wrongdoing
    • Observatory on Patents and Technology
      • Go back
      • Overview
      • Innovation against cancer
      • Innovation actors
        • Go back
        • Overview
        • Startups and SMEs
      • Policy and funding
        • Go back
        • Overview
        • Financing innovation programme
          • Go back
          • Overview
          • Our studies on the financing of innovation
          • EPO initiatives for patent applicants
          • Financial support for innovators in Europe
        • Patents and standards
          • Go back
          • Overview
          • Publications
          • Patent standards explorer
      • Tools
        • Go back
        • Overview
        • Deep Tech Finder
      • About the Observatory
        • Go back
        • Overview
        • Work plan
    • Transparency portal
      • Go back
      • Overview
      • General
        • Go back
        • Overview
        • Annual Review 2023
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • 50 years of the EPC
          • Strategic key performance indicators
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
        • Annual Review 2022
          • Go back
          • Overview
          • Foreword
          • Executive summary
          • Goal 1: Engaged and empowered
          • Goal 2: Digital transformation
          • Goal 3: Master quality
          • Goal 4: Partner for positive impact
          • Goal 5: Secure sustainability
      • Human
      • Environmental
      • Organisational
      • Social and relational
      • Economic
      • Governance
    • Statistics and trends
      • Go back
      • Overview
      • Statistics & Trends Centre
      • Patent Index 2024
        • Go back
        • Insight into computer technology and AI
        • Insight into clean energy technologies
        • Statistics and indicators
          • Go back
          • European patent applications
            • Go back
            • Key trend
            • Origin
            • Top 10 technical fields
              • Go back
              • Computer technology
              • Electrical machinery, apparatus, energy
              • Digital communication
              • Medical technology
              • Transport
              • Measurement
              • Biotechnology
              • Pharmaceuticals
              • Other special machines
              • Organic fine chemistry
            • All technical fields
          • Applicants
            • Go back
            • Top 50
            • Categories
            • Women inventors
          • Granted patents
            • Go back
            • Key trend
            • Origin
            • Designations
      • Data to download
      • EPO Data Hub
      • Clarification on data sources
    • History
      • Go back
      • Overview
      • 1970s
      • 1980s
      • 1990s
      • 2000s
      • 2010s
      • 2020s
    • Art collection
      • Go back
      • Overview
      • The collection
      • Let's talk about art
      • Artists
      • Media library
      • What's on
      • Publications
      • Contact
      • Culture Space A&T 5-10
        • Go back
        • Catalyst lab & Deep vision
          • Go back
          • Irene Sauter (DE)
          • AVPD (DK)
          • Jan Robert Leegte (NL)
          • Jānis Dzirnieks (LV) #1
          • Jānis Dzirnieks (LV) #2
          • Péter Szalay (HU)
          • Thomas Feuerstein (AT)
          • Tom Burr (US)
          • Wolfgang Tillmans (DE)
          • TerraPort
          • Unfinished Sculpture - Captives #1
          • Deep vision – immersive exhibition
          • Previous exhibitions
        • The European Patent Journey
        • Sustaining life. Art in the climate emergency
        • Next generation statements
        • Open storage
        • Cosmic bar
      • "Long Night"
  • Boards of Appeal
    • Go back
    • Overview
    • Decisions of the Boards of Appeal
      • Go back
      • Overview
      • Recent decisions
      • Selected decisions
    • Information from the Boards of Appeal
    • Procedure
    • Oral proceedings
    • About the Boards of Appeal
      • Go back
      • Overview
      • President of the Boards of Appeal
      • Enlarged Board of Appeal
        • Go back
        • Overview
        • Pending referrals (Art. 112 EPC)
        • Decisions sorted by number (Art. 112 EPC)
        • Pending petitions for review (Art. 112a EPC)
        • Decisions on petitions for review (Art. 112a EPC)
      • Technical Boards of Appeal
      • Legal Board of Appeal
      • Disciplinary Board of Appeal
      • Presidium
        • Go back
        • Overview
    • Code of Conduct
    • Business distribution scheme
      • Go back
      • Overview
      • Technical boards of appeal by IPC in 2025
      • Archive
    • Annual list of cases
    • Communications
    • Annual reports
      • Go back
      • Overview
    • Publications
      • Go back
      • Abstracts of decisions
    • Case Law of the Boards of Appeal
      • Go back
      • Overview
      • Archive
  • Service & support
    • Go back
    • Overview
    • Website updates
    • Availability of online services
      • Go back
      • Overview
    • FAQ
      • Go back
      • Overview
    • Publications
    • Ordering
      • Go back
      • Overview
      • Patent Knowledge Products and Services
      • Terms and conditions
        • Go back
        • Overview
        • Patent information products
        • Bulk data sets
        • Open Patent Services (OPS)
        • Fair use charter
    • Procedural communications
    • Useful links
      • Go back
      • Overview
      • Patent offices of member states
      • Other patent offices
      • Directories of patent attorneys
      • Patent databases, registers and gazettes
      • Disclaimer
    • Contact us
      • Go back
      • Overview
      • Filing options
      • Locations
    • Subscription centre
      • Go back
      • Overview
      • Subscribe
      • Change preferences
      • Unsubscribe
    • Official holidays
    • Glossary
    • RSS feeds
Board of Appeals
Decisions

Recent decisions

Overview
  • 2025 decisions
  • 2024 decisions
  • 2023 decisions
  1. Home
  2. T 1150/09 14-11-2013
Facebook X Linkedin Email

T 1150/09 14-11-2013

European Case Law Identifier
ECLI:EP:BA:2013:T115009.20131114
Date of decision
14 November 2013
Case number
T 1150/09
Petition for review of
-
Application number
01943357.2
IPC class
C07K 16/22
Language of proceedings
EN
Distribution
NO DISTRIBUTION (D)

Download and more information:

Decision in EN 175.24 KB
Documentation of the appeal procedure can be found in the European Patent Register
Bibliographic information is available in:
EN
Versions
Unpublished
Application title

Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage

Applicant name

Vlaams Interuniversitair Instituut voor Biotechnologie vzw.

D. Collen Research Foundation vzw.

Opponent name
STRAWMAN LIMITED
Board
3.3.04
Headnote
-
Relevant legal provisions
European Patent Convention Art 83
European Patent Convention Art 123(2)
Rules of procedure of the Boards of Appeal Art 13(1)
Rules of procedure of the Boards of Appeal Art 13(3)
Keywords

Main request, auxiliary requests 1 to 5 - sufficiency of disclosure (no)

Auxiliary requests 7 and 8 - admitted (no)

Catchword
-
Cited decisions
G 0005/83
R 0002/08
R 0012/09
R 0015/10
R 0013/11
T 0019/90
T 0609/02
T 0801/06
T 0183/09
Citing decisions
T 1958/16
T 0395/18

I. The appeal of the opponent (hereafter "appellant") lies against the decision of the opposition division posted on 27 March 2009, whereby European patent No. EP 1297016 was maintained in amended form on the basis of auxiliary request 1 filed on 28 November 2008.

II. The patent at issue has the title "Use of inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumour formation and/or vascular leakage". It was granted on European application No. 01943357.2 which originated from international application PCT/EP2001/005478 published as WO 2001/085796 (hereinafter "application as filed").

III. The patent was opposed under Article 100(a) EPC 1973 on the grounds of lack of novelty (Article 54 EPC 1973) and lack of inventive step (Article 56 EPC 1973), under Article 100(b) EPC 1973 and under Article 100(c) EPC 1973.

IV. The opposition division decided that the claims of the auxiliary request 1 (which corresponds to the present main request) fulfilled the requirements of the EPC.

V. The appellant filed its statement of grounds of appeal on 6 August 2009 including substantial arguments why the claims upheld by the opposition division inter alia failed to meet the requirements of Article 83 EPC.

VI. In response the proprietors (hereafter "respondents") filed a reply on 22 January 2010, submitting the claims allowed by the opposition division as their main request and filing five auxiliary requests. Claim 1 of the main request reads as follows: "1. Use of an angiogenesis inhibitor consisting of an antibody or a fragment thereof specifically binding to placental growth factor for the preparation of a medicament for the treatment of cancer, pulmonary hypertension, inflammation, oedema, retinopathy of prematurity, diabetic retinopathy, choroidal and other intraocular disorders, and retinal ischemic diseases." (Emphasis added). Claim 1 of auxiliary request 1 reads as follows: "1. Use of an angiogenesis inhibitor consisting of an antibody or a fragment thereof specifically binding to placental growth factor for the preparation of a medicament for the treatment of cancer, pulmonary hypertension, inflammation, oedema, retinopathy of prematurity, diabetic retinopathy, choroidal and other intraocular disorders, and retinal ischemic diseases, with the proviso that said angiogenesis inhibitor is not for use as a medicament in combination with a molecule specifically binding to VEGF." (Emphasis added). Claim 1 of auxiliary request 2 reads as follows: "1. Use of an angiogenesis inhibitor consisting of an antibody or a fragment thereof specifically binding to placental growth factor for the preparation of a medicament for the treatment of cancer, pulmonary hypertension, oedema, retinopathy of prematurity, diabetic retinopathy, choroidal and other intraocular disorders, and retinal ischemic diseases." (Emphasis added). Claim 1 of auxiliary request 3 reads as follows: "1. Use of an angiogenesis inhibitor consisting of an antibody or a fragment thereof specifically binding to placental growth factor for the preparation of a medicament for the treatment of cancer, pulmonary hypertension, inflammation, and oedema." (Emphasis added). Claim 1 of auxiliary request 4 reads as follows: "1. Use of an angiogenesis inhibitor consisting of an antibody or a fragment thereof specifically binding to placental growth factor for the preparation of a medicament for the treatment of cancer, pulmonary hypertension, and oedema." (Emphasis added). Claim 1 of auxiliary request 5 reads as follows: "1. Use of an angiogenesis inhibitor consisting of an antibody or a fragment thereof specifically binding to placental growth factor for the preparation of a medicament for the treatment of cancer." (Emphasis added).

VII. By a communication of 16 January 2013 the parties were summoned to oral proceedings to be held on 14 November 2013.

VIII. In its letter of 8 October 2013 the appellant announced that it would not attend the oral proceedings scheduled for 14 November 2013.

IX. Oral proceedings before the board were held on 14 November 2013 in the absence of the appellant. At the request of the respondents the board expressed its view on the objection raised by the appellant with respect to the issue of sufficiency of disclosure. Thereafter the respondents provided their arguments. After the board expressed its view that the disclosure was insufficient as regards the treatment of cancer and that this view affected all pending requests the respondents filed auxiliary requests 6 and 7. The board expressed its surprise at the proposed amendments and questioned the likelihood of overcoming the objection under Article 100(b) EPC which prompted the respondents to withdraw auxiliary request 6. The board heard the respondents on the admissibility of auxiliary request 7 and decided not to admit auxiliary request 7. The respondents then filed auxiliary request 8. The board heard the respondents on the admissibility of auxiliary request 8 and decided not to admit it. After the board announced its decision not to admit auxiliary request 8 in the proceedings, the respondents requested an adjournment of the oral proceedings. After resumption of the oral proceedings the respondents stated that there had been a procedural defect. The respondents submitted that the board should have admitted auxiliary request 8 because, in accordance with decision T 183/09, a request which addressed an issue raised during oral proceedings should be allowed. The respondents had been expected to address an issue during oral proceedings which required more preparation and which was not anticipated on their own reading of the appellant's argument. They were considering a petition for review on the ground that their right to be heard had been violated (cf. minutes). Claim 1 of auxiliary request 7 reads as follows: "1. Use of an angiogenesis inhibitor consisting of an antibody or a fragment thereof specifically binding to placental growth factor for the preparation of a medicament for the treatment of carcinomas, sarcomas, carcinosarcoma, tumours of nerve tissues, melanoma, pulmonary hypertension, inflammation, oedema, retinopathy of prematurity, diabetic retinopathy of prematurity, choroidal and other intraocular disorders, and retinal ischemic diseases." (Emphasis added). Claim 1 of auxiliary request 8 reads as follows: "1. Use of an angiogenesis inhibitor consisting of an antibody or a fragment thereof specifically binding to placental growth factor for the preparation of a medicament for the treatment of pulmonary hypertension, inflammation, oedema, retinopathy of prematurity, diabetic retinopathy, choroidal and other intraocular disorders, and retinal ischemic diseases."

X. Documents referred to in this decision:

(D7) Tumour angiogenesis, R. Bicknell, C.E. Lewis, and N. Ferrara editors, pages 1-18 (1997)

(D10) Nomura M. et al., J. Neuro-Oncology, vol. 40, pages 123-130 (1998)

(D15) Ryan A.M. et al., Toxicologic Pathology, vol. 27, pages 78-86 (1999)

(D16) Experimental data filed by letter dated 24 March 2005

(D21) Carmeliet P., Verhandelingen, vol. 62, pages 31-68 (2000)

XI. The relevant arguments of the appellant in writing can be summarised as follows: Main request Amendments (Article 100(c) EPC) - claim 1 The term "consisting of" as applied to the angiogenesis inhibitor added subject-matter. There was no direct and unambiguous disclosure of the angiogenesis inhibitor being specifically limited to consisting of an antibody or a fragment thereof. Indeed the application as filed allowed for the possibility of additional components within the angiogenesis inhibitor (page 6, lines 23 to 24). Sufficiency of disclosure (Articles 100(b) and 83 EPC) Decisions T 792/00, T 187/93 and T 609/02 were highly pertinent to the present case. There was in the patent not one example of inhibition of PlGF using an antibody to inhibit angiogenesis in a valid disease model for any of the diseases as claimed. In the experiments disclosed in the patent, the lesion studied was introduced or induced in the mice after knock-out of the PlGF genes and this was in contrast to any pathological situation in which the lesion already existed and where PlGF was already present in the system.

The disclosure in the patent provided no more than the beginnings of a research program of uncertain outcome and for the skilled person, to be able to carry out the invention as claimed, would require the exercise of an undue burden of experimentation. The patent disclosure itself should put the skilled person in possession of at least one way of putting the claimed invention into practice, as well as provide a sufficient disclosure across the whole scope of the claims. There was no definition of "cancer" in the specification and therefore claim 1 appeared to cover all cancers. In fact, no evidence was provided that PlGF was involved in all cancers. Treatment of tumour formation was addressed in the specification to the extent that a generic list of various types of tumours was provided (page 6, paragraphs [0016] and [0017]), however no indication was given regarding which of the tumours were suitable for treatment using anti-PlGF antibodies and indeed if PlGF was actually involved in the formation of any of these tumours. It was well known in the art at the priority date of the application that PlGF was not expressed in all tumours, for example see document (D10). Indeed it was known that the involvement of PlGF might be dependent on the origin of the tumour. The patent provided no teaching of which tumours would be suitable for treatment with a PlGF inhibitor or how the skilled person should identify such a tumour. The skilled person was expected to predict which cancers might be suitable for the anti-PlGF treatment without guidance from the specification. An undue burden was placed on the skilled person to perform extensive experimentation to clarify which cancers were suitable for treatment with an anti-PlGF antibody in order to perform the invention as claimed in claim 1. Thus the disclosure was insufficient for the skilled person to be able to carry out the whole subject-matter defined in the claims without undue burden.

XII. The relevant arguments of the respondents can be summarised as follows: Main request Amendments (Article 100(c) EPC) - claim 1 The application as filed provided a basis for "consisting of" on page 5, lines 1 to 14, on page 3, lines 23 to 31, the example section as a whole and claim 6. Sufficiency of disclosure (Articles 100(b) and 83 EPC) In the written procedure the respondents argued that it was well established by the EPO case law that an opponent carried the burden of proving insufficiency, see decision T 19/90 (reasons, point 3.3), and the Case Law of the Boards of Appeal of the EPO (5th edition, page 179, third paragraph). The appellant had failed to provide any evidence ("verifiable facts") to support its sufficiency objections and therefore it had failed to discharge its burden of proof. The application as filed contained ample experimental evidence supporting the utility (sic) of anti-PlGF antibodies in the inhibition of pathological angiogenesis. The utility (sic) of the present invention was also confirmed by post-filed data, notably document (D16). During the oral proceedings the respondent argued that the experiment described in the patent rendered the claimed therapeutic effect of inhibiting PlGF plausible and document (D16) confirmed it. There was no indication in the prior art that removal of PlGF was sufficient to treat cancer. The patent indicated that PlGF produced by the tissue surrounding the tumour played a role in the growth of the tumour and this irrespective of whether or not the tumour itself produced PlGF. It was irrelevant that not all tumours produced PlGF because PlGF affected the response of cells to VEGF. Therefore removal of PlGF had an effect regardless of whether or not the tumour expressed PlGF. Documents (D7), (D15) and (D21) confirmed that VEGF played a role in a variety of solid tumours. Auxiliary requests 1 to 5 Sufficiency of disclosure (Article 100(b) and 83 EPC) No further arguments were provided. Auxiliary request 7 Admissibility The request should be admitted because it addressed the objection discussed during oral proceedings. Claim 1 has now been restricted to cancers known to be VEGF dependent.

Auxiliary request 8 Admissibility The request should be admitted because it addressed the objection raised by the appellant by deleting any reference to cancer. It was admittedly filed at a late stage but it had not been envisaged that the board would agree with the appellant as to lack of sufficiency regarding the treatment of cancer.

XIII. The appellant requested in writing that the decision under appeal be set aside and that the patent be revoked. The respondents request that the appeal be dismissed or that the decision under appeal be set aside and that the patent be maintained on the basis of one of their auxiliary requests 1 to 5 filed with their reply to the statement of grounds of appeal or auxiliary requests 7 and 8 filed during the oral proceedings.

Main request

Amendments (Article 100(c) EPC) - claim 1

1. The board is satisfied that the application as filed provides a basis for the feature "consisting of" on page 5, lines 1 to 14, on page 3, lines 23 to 31, in the example section as a whole and in claim 6. In view of the decision on sufficiency of disclosure, see below, the board considers it unnecessary to provide a detailed reasoning for its finding.

Sufficiency of disclosure (Articles 100(b) and 83 EPC)

2. Claim 1 is drafted in the so-called Swiss-type format and relates to the use of an angiogenesis inhibitor consisting of an antibody or a fragment thereof specifically binding to placental growth factor (PlGF) for the preparation of a medicament for the treatment of inter alia cancer (see section VI above for the complete wording of claim 1).

3. As a first line of argument the appellant submitted that there was no exemplification of inhibition of PlGF to inhibit angiogenesis using an antibody to achieve any technical effect in any valid model relevant to the treatment of cancer because in the experiment disclosed in the patent the lesion studied was induced in mice after knock-out of the PlGF genes, i.e. in the absence of PlGF.

4. The board notes that it is established jurisprudence of the Boards of Appeal that where, as in the present case, a therapeutic application is claimed in the form allowed by the Enlarged Board of Appeal in decision G 5/83 (OJ EPO 1985, 64), i.e. in the form of the use of a substance or composition for the manufacture of a medicament for a defined therapeutic application, attaining the claimed therapeutic effect is a functional technical feature of the claim. As a consequence, under Article 83 EPC, unless this is already known to the skilled person at the priority date, the application must disclose the suitability of the product to be manufactured for the claimed therapeutic application. It has been established by the case law relating to sufficiency of disclosure with regard to claims to a second medical use, that a claimed therapeutic effect may be proven by any kind of data as long as they directly and unambiguously reflect the therapeutic application (cf. Case Law of the Boards of Appeal of the European Patent Office, 7th edition 2013, section II.C.6.2, and decisions T 609/02 of 27 October 2004, reasons, point 9 and T 801/06 of 4 March 2009, reasons, point 28).

5. Therefore, in the board's judgement the mere fact that the experiments were carried out in knock-out mice does not in itself suffice to deny sufficiency of disclosure. Rather, the question to be addressed is whether or not the data provided in the patent in suit reflect the claimed therapeutic application.

6. Example 1 of the patent in suit (cf paragraph [0025]) entitled "Impaired pathological angiogenesis in PlGF**(-/-) mice" is the relevant example. In this example, the growth and angiogenesis of embryonic stem (ES) cell-derived tumours, known to be mediated by VEGF, were studied in nu/nu PlGF**(-/-) mice and shown to be also dependent on PlGF. Indeed, PlGF**(+/+) ES cell-derived tumours, obtained within four weeks after subcutaneous inoculation in nu/nu PlGF**(+/+) mice, weighed 4 ± 1 g (n=8) and appeared haemorrhagic and bled profusely (7 of 8 tumours). In contrast, PlGF**(-/-)tumours in nu/nu PlGF**(-/-) hosts only weighed 1.0 ± 0.3 g (n=8) and were homogeneously white with minimal bleeding (5 of 7 tumours). Growth and vascularization in PlGF**(-/-)tumours were reduced to the same degree as in VEGF**(-/-)tumours. PlGF**(+/+)and PlGF**(-/-)tumours contained comparable vascular densities of endothelial cords and capillaries. However, compared to PlGF**(+/+) tumours, PlGF**(-/-)tumours contained fewer medium-sized or large vessels. Angiogenesis of PlGF**(+/+) tumours in nu/nu PlGF**(-/-) mice or of PlGF**(-/-) tumours in nu/nu PlGF**(+/+) mice was comparable to that of PlGF**(+/+) tumours in nu/nu PlGF**(+/+) mice, indicating that production of PlGF either by tumour or by host-derived tissue could rescue the phenotype.

7. The board is satisfied that example 1 demonstrates that the absence of PlGF has an effect on the growth and vascularisation of ES cell-derived tumours (which are known to be VEGF dependent). That tumour growth was assessed in mice where the PlGF genes had been knocked-out before inducing the tumour can not detract from the fact that absence of PlGF has been shown to have an effect that reflects a therapeutic application. In the board's judgement the results obtained in the knock-out mice render the therapeutic application of inhibiting angiogenesis by using an antibody which binds to PlGF in the context studied, i.e. growth and angiogenesis of ES cell-derived tumours, known to be mediated by VEGF, and wherein either the tumour or the surrounding tissue is known to produce PlGF, at least plausible for the skilled person. The board notes however that there is no evidence on file that this context reflects a mechanism which would be common to all cancers. Finally, document (D16), a post-filed document, confirms that in the four solid tumour models tested, injection of monoclonal anti-PlGF antibody resulted in a significant reduction of tumor volume and size.

8. In a further line of argument the appellant argued that the disclosure was insufficient for the skilled person to carry out the claimed invention without undue burden. The skilled person had to perform extensive experimentation to clarify which cancers were suitable for the treatment with an anti-PlGF antibody in order to perform the invention as claimed, and this constituted an undue burden.

9. It is established jurisprudence of the Boards of Appeal that the requirement of sufficiency of disclosure is met only if the invention as defined in the claims can be performed by a person skilled in the art over the whole range claimed without undue burden, using common general knowledge and having regard to the information provided in the patent. This principle applies to any invention irrespective of the way in which it is defined and is a question of fact to be decided on a case-by-case basis (cf Case Law of the Boards of Appeal of the European Patent Office, 7th edition 2013, sections II.C.4.1., 4.2. and 4.4).

10. The appellant argued, and this has not been contested by the respondents, that there is no definition of "cancer" in the specification. Therefore claim 1 embraces the treatment of any and all cancers and is not restricted to the treatment of tumours for which an involvement of PlGF on tumour formation is known to the skilled person. Furthermore, from document (D10) it was known in the art at the relevant date that PlGF is not expressed in all tumours and that the involvement of PlGF might be dependent on the origin of the tumour.

11. Indeed, document (D10) investigates the expression of PlGF in brain tumours and discloses that PlGF was found to be expressed in 25 out of 39 brain tumours. While PlGF mRNA is expressed in all the hypervascular brain tumors, PlGF mRNA is not common in hypovascular tumors and no PlGF mRNA was detected in the metastatic hypervascular brain tumors tested. The authors conclude that the involvement of PlGF in tumor angiogenesis may depend on the origin of the tumors (cf abstract and paragraph bridging pages 128 and 129).

12. In the board's judgement document (D10) provides evidence that PlGF is not involved in the angiogenesis of all cancers. For the invention underlying claim 1 to be sufficiently disclosed, the skilled person must therefore be able to select without undue burden those cancers that are treatable by using an angiogenesis inhibitor consisting of an antibody or a fragment thereof specifically binding to PlGF.

13. The patent in suit does not indicate which criteria the skilled person should apply for identifying a cancer which can be treated with an angiogenesis inhibitor consisting of an antibody or a fragment thereof specifically binding to PlGF. The specification of the patent merely addresses the treatment of tumour formation in the general part of the description to the extent that a generic list of various types of tumours is provided (cf paragraphs [0016] and [0017]) however no indication is given regarding which of the tumours are actually suitable for treatment using anti-PlGF antibodies in accordance with the invention and whether or not PlGF is actually involved in the formation of any of these tumours. Thus, the skilled person wanting to perform the claimed invention is expected to predict which cancers might be suitable for the anti-PlGF treatment without guidance from the specification. Moreover, there is no evidence on file that the skilled person is able to select cancers amenable to the claimed treatment on the basis of his/her common general knowledge. This has not been contested by the respondents.

14. The board concludes from the above that the skilled person was not in a position to predict, on the basis of the information contained in the specification and taking into account the relevant common general knowledge, which cancers can be treated in accordance with the invention. Accordingly, such cancers have to be identified by carrying out further tests for which the patent also provides no guidance. Therefore the skilled person is in a position where he/she has to carry out a research program to clarify which cancers are suitable for the treatment with an angiogenesis inhibitor consisting of an antibody or a fragment thereof specifically binding to PlGF in order to perform the invention as claimed in claim 1. The board judges that in the present case this amounts to an undue burden for the skilled person. Accordingly, the claimed invention suffers from insufficiency of disclosure.

15. As a first line of argument in defence the respondents relied on decision T 19/90 (OJ EPO 1990, 476, reasons, point 3.3) and submitted that the appellant had failed to provide any evidence ("verifiable facts") to support its sufficiency objections and had therefore failed to discharge its burden of proof.

16. The board notes that decision T 19/90, supra, reads at the relevant passage relied on by the respondents as follows: "Only if there are serious doubts, substantiated by verifiable facts, may an application be objected to for lack of sufficient disclosure". The board understands this passage to mean that verifiable facts are required to substantiate an objection as to lack of sufficiency of disclosure. In the board's judgement it is a verifiable fact that claim 1 is directed to the treatment of any and all cancers while the patent is silent as to which cancers are amenable to treatment with an antibody that binds to PlGF. It is also a verifiable fact that the patent provides no guidance as to how the skilled person should identify those cancers that are amenable to treatment. It is a further verifiable fact that not all cancers express PlGF. The evidence which supports these verifiable facts is on the one hand the patent specification of the patent in suit and on the other hand document (D10). The board therefore considers it established by the appellant that not all cancers are treatable with an angiogenesis inhibitor consisting of an antibody or a fragment thereof specifically binding to PlGF. The board concludes that the appellant has discharged its burden of proof for arguing lack of sufficiency of disclosure of the invention in claim 1 in its broadest form. Accordingly, it is for the respondents to present refuting facts and/or arguments.

17. The respondents have not provided any refuting facts or arguments in the written appeal proceedings other than that (i) the application as filed contained ample experimental evidence supporting the utility of anti-PlGF antibodies in the inhibition of pathological angiogenesis and (ii) that the utility of the present invention was also confirmed by post-filed data, notably document (D16).

18. In the board's judgement these arguments advanced by the respondents address merely the first issue raised by the appellant (see point 3, above), but do not begin to address the second one (see point 8, above), namely that the skilled person faces an undue burden when trying to work the invention across the whole scope of claim 1. The evidential value of the data disclosed in the patent in suit and in document (D16) has already been discussed above (see points 4 to 7, above).

19. During the oral proceedings the respondents argued that it was irrelevant that not all tumours expressed PlGF because PlGF affected the response of tumour cells to VEGF. The example in the patent demonstrated that PlGF produced by the tissue surrounding the tumour played a role in the growth of the tumour and this irrespective of whether or not the tumour itself produced PlGF. Therefore removal of PlGF had an effect regardless of whether or not the tumour expressed PlGF. Document (D7) at page 2, left hand column, lines 16 to 14 from bottom; document (D15) at page 78, left hand column, first paragraph; and document (D21) at page 37, first full paragraph were referred to in order to provide evidence that VEGF played a role in a variety of solid tumours.

20. The board does not consider this line of reasoning persuasive. Firstly, it is a fact that the term "cancer" is not synonymous with solid tumours but embraces any and all cancers including cancers of the blood-forming tissues, such as leukemias and lymphomas (see paragraph [0017] of the patent in suit). In fact, no evidence is on file that angiogenesis, VEGF or PlGF is involved at all in these types of cancers, neither in the patent in suit nor in the prior art relied on by the respondents. From the prior art (see document (D10), page 123 LHC, first paragraph) it would appear that it was speculated that angiogenesis might contribute to the growth, progression and metastasis of several types of solid tumours but the prior art referred to by the respondents is silent on the role of any of PlGF or VEGF on any other type of cancers such as for example cancers of the blood-forming tissues.

21. Secondly, the argument by the respondents that PlGF might also be produced by the surrounding tissue fails to address the problem that the skilled person is given no guidance in the patent as to which cancers can be treated in the first place. Even if PlGF were to be produced by the surrounding tissue and not by the cancer itself, the patent in suit does not identify these tissues and in the absence of any relevant common general knowledge the skilled person still has to test for the presence of PlGF in the surrounding tissue in order to identify whether or not a cancer is amenable to the treatment with an angiogenesis inhibitor consisting of an antibody or a fragment thereof specifically binding to PlGF. The skilled person would thus be in a similar situation as with the cancer itself, i.e. he/she would have to carry out further tests without any guidance. Therefore the respondents’ arguments fail.

22. In conclusion, the board, having regard to the facts and arguments presented to it, decides that the disclosure of the contested patent does not allow the skilled person to perform the invention across the whole scope claimed without undue burden so that there is insufficiency of disclosure.

Auxiliary requests 1 to 5 Sufficiency of disclosure (Articles 100(b) and 83 EPC)

23. Auxiliary requests 1 to 4 include and auxiliary request 5 is limited to the treatment of cancer. The respondents submitted no further arguments for these requests and conceded that the objections that applied to the main request also applied to these requests. Accordingly these requests fail the requirement of sufficiency of disclosure for the same reasons as indicated above (cf. points 7 to 14) for the main request.

Auxiliary request 7

Admissibility

24. This request was filed during the oral proceedings after the board expressed its view that claim 1 of all requests on file failed the requirements of sufficiency of disclosure. Auxiliary request 7 is based on the main request and differs therefrom in that in claim 1 the term "cancer" is replaced by the terms "carcinomas, sarcomas, carcinosarcoma, tumours of nerve tissues, melanoma" (see section VI above for the complete wording of claim 1). The respondents submitted that the request should be admitted because it addressed the objection discussed during oral proceedings by limiting the claim to cancers known to be VEGF dependent. The request was admittedly late filed but the respondents argued in their defence that they had not envisaged that the board would agree with the appellant as to lack of sufficiency regarding the treatment of cancer.

25. The board notes that the appellant had raised the objection as to lack of sufficiency of disclosure already in its notice of opposition and had maintained its objection on appeal. The respondents were aware of this objection upon the receipt of the statement of the grounds of appeal of the appellant. In their reply to the statement of grounds of appeal, the respondents maintained the request underlying the decision under appeal as main request and filed five auxiliary requests. All these requests included the treatment of cancer and auxiliary request 5 had been limited to cancer as the sole disease to be treated.

26. It is for the respondents to defend their case as they see fit. This includes the timely submission of their fall back positions in the form of auxiliary requests (Article 12(2) RPBA). That the respondents considered the case made by the appellant as not persuasive can be no justification for addressing the objection as to lack of sufficiency of disclosure at such a late stage of the proceedings. In addition, the board notes that in this request features from the description were incorporated into the claims which were not present in any of the claims of any of the requests on file. This type of amendment was not foreseeable either for the appellant or the board and came as a surprise. Therefore the board decided not to admit auxiliary request 7 in the proceedings (Articles 13(1) and (3) RPBA).

Auxiliary request 8

Admissibility

27. This request was also filed during the oral proceedings. It is based on the main request and differs therefrom in that the term "cancer" has been deleted from claim 1. The respondents submitted that the request should be admitted because it addressed the objection discussed. The respondents conceded that the request was late filed but reiterated that they had not envisaged that the board would agree with the appellant as to lack of sufficiency of disclosure regarding the treatment of cancer.

28. As set out above (see point 25), the respondents were aware of the objection since the receipt of the statement of the grounds of appeal of the appellant. Therefore, this request could have been filed earlier and was thus late-filed. That the respondents considered the case made by the appellant as not persuasive and awaited the view of the board before filing auxiliary request 8 can be no justification for addressing the objection as to lack of sufficiency of disclosure at such a late stage of the proceedings. Auxiliary request 8 is based on the main request but removes for the first time the most preferred embodiment which was present in all requests filed pursuant to Article 12(2) RPBA and to which auxiliary request 5 indeed had been limited. With this amendment the respondent shifted the subject-matter claimed in an unexpected manner in a different direction. It is established jurisprudence of the Boards of Appeal that the very late filing of diverging auxiliary requests runs counter the need for procedural economy (cf Case Law of the Boards of Appeal of the European Patent Office, 7th edition 2013, section VII.E.4.4.4). Therefore the board decided not to admit auxiliary request 8 in the proceedings because it was late filed, it could have been filed earlier and admitting the request into the proceedings would run counter to the need for procedural economy and to the principle of procedural fairness (Articles 13(1) and (3) RPBA).

29. After the board had announced its decision on the admissibility of their auxiliary request 8 filed during the oral proceedings, the respondents submitted (see section IX above) that the board should have admitted that request because, in accordance with decision T 183/09 of 9 September 2010, a request which addressed an issue raised during oral proceedings should be admitted. This was however the first occasion on which the respondents made that submission and by that point in time the board had, after hearing the respondents on the admissibility of that request, made and announced its decision.

30. The respondents also submitted at this point (again, see section IX above) that they had been expected to address an issue during oral proceedings which required more preparation and which was not anticipated on their own reading of the appellant's argument. While the board accepts that the respondents did not expect the appellant's argument on insufficiency to succeed, that argument was clearly set out in the statement of grounds of appeal. In their reply the respondents elected to deal with the issue of insufficiency only by relying on the argument that the appellant had not provided evidence (see section XII above). At the oral proceedings the respondents indeed appeared less than fully prepared to deal with the issue but, however unfortunate, that was the result of their appraisal of the issue or, as they said in their own submission, their reading of the appellant's argument. As mentioned above (see point 26) in the context of the admissibility of the respondents' requests, it was for the respondents to defend their case as they saw fit. They were responsible for the conduct of their case and it was for them to submit the necessary arguments to support their case on their own initiative and at the appropriate time (see R 2/08 of 11 September 2008, reasons, points 8.5 and 9.10). If the respondents were surprised by the result, such surprise may be an understandable subjective reaction but such subjective surprise cannot change the fact that they knew the issue would be raised and had an opportunity to prepare their position and to present that position both in writing and at the oral proceedings (see R 12/09 of 15 January 2010, reasons, point 13; R 15/10 of 25 November 2010, reasons, point 11; and R 13/11 of 20 April 2012, reasons, point 18).

31. The board concludes that all admissible requests fail the requirements of Article 83 EPC. Accordingly, the patent cannot be maintained on any of these requests and, in the absence of another, allowable claim request, the patent has to be revoked.

Order

ORDER

For these reasons it is decided that:

1. The decision under appeal is set aside.

2. The patent is revoked.

Footer - Service & support
  • Service & support
    • Website updates
    • Availability of online services
    • FAQ
    • Publications
    • Procedural communications
    • Contact us
    • Subscription centre
    • Official holidays
    • Glossary
Footer - More links
  • Jobs & careers
  • Press centre
  • Single Access Portal
  • Procurement
  • Boards of Appeal
Facebook
European Patent Office
EPO Jobs
Instagram
EuropeanPatentOffice
Linkedin
European Patent Office
EPO Jobs
EPO Procurement
X (formerly Twitter)
EPOorg
EPOjobs
Youtube
TheEPO
Footer
  • Legal notice
  • Terms of use
  • Data protection and privacy
  • Accessibility